Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
J. H. Strickler
No relevant relationships to disclose
A. L. Cohn
No relevant relationships to disclose
C. Arrowood
No relevant relationships to disclose
S. Haley
No relevant relationships to disclose
M. Morse
Consultant or Advisory Role - Genentech
Honoraria - Bristol-Myers Squibb; Genentech
H. Uronis
Research Funding - Bristol-Myers Squibb
G. C. Blobe
Consultant or Advisory Role - Roche
Honoraria - Roche
S. D. Hsu
No relevant relationships to disclose
Y. Zafar
Honoraria - Genentech
H. Hurwitz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; Roche